Continue to Innovate Services, Therapies and Products

Recombinate

rAHF-PFM

2002 Portfolio

Future

2003-2005

Next Gen Therapies

Continue to Innovate Recombinant FVIII Products

rFVIII Portfolio

• Introduced in 1992

• 1st genetically engineered FVIII

• ɰB units of rFVIII infused to date

• Advancing research on improved FVIII delivery and administration

• First recombinant FVIII manufactured without added human or animal proteins

Previous slide

Next slide

Back to first slide

View graphic version